Key result
Trial design outlines IV iron testing for mortality, heart failure, and physical function in CKD.
Why the study?
Does intravenous iron improve survival and physical function and reduce heart failure events in patients with chronic kidney disease?
Does intravenous iron improve survival and physical function and reduce heart failure events in patients with chronic kidney disease?
The authors propose a randomized trial to evaluate the efficacy of intravenous iron on mortality, heart failure, and physical function in patients with chronic kidney disease, independent of hemoglobin levels.
AbstractIron deficiency is common in patients with chronic kidney disease (CKD). Contemporary guidelines recommend the use of iron therapy only in the presence of anemia. However, patients with CKD are at increased risk of heart failure, and the coexistence of both conditions is associated with impaired quality of life, reduced physical function, and increased mortality compared with either condition alone. In this Tomorrow's Trial article, we review current evidence for intravenous iron in CKD and heart failure and propose the design of a randomized trial of intravenous iron, independent of hemoglobin, to assess its effects on mortality, heart failure, and physical function.
No takes yet. Share an insight, caveat, or question.
Neuen et al. (2026) conducted a review in Chronic Kidney Disease. Intravenous iron was evaluated on Mortality, heart failure, and physical function. This article reviews current evidence and proposes the design of a randomized trial to assess the effects of intravenous iron on mortality, heart failure, and physical function in patients with CKD.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: